Fragile X-associated primary ovarian insufficiency: Evidence for additional genetic contributions to severity

Genetic Epidemiology

Volumn 32, Issue 6, 2008, Pages 553-559

  Hunter, Jessica Ezzell ^a   Epstein, Michael P ^a   Tinker, Stuart W ^a   Charen, Krista H ^a   Sherman, Stephanie L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CGG repeat; Fragile X syndrome; Premature ovarian failure; Premutation; Triplet repeat

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

ADULT; AGE; AGED; ANAMNESIS; ARTICLE; BODY MASS; DISEASE SEVERITY; FAMILY; FEMALE; FRAGILE X SYNDROME; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY INSUFFICIENCY; PATIENT COUNSELING; PROPORTIONAL HAZARDS MODEL; RACE; SMOKING;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MENOPAUSE; MIDDLE AGED; OVARIAN FAILURE, PREMATURE; PROPORTIONAL HAZARDS MODELS; QUANTITATIVE TRAIT, HERITABLE; RISK FACTORS; TRINUCLEOTIDE REPEATS;

EID: 51749122389     PISSN: 07410395     EISSN: 10982272     Source Type: Journal    
DOI: 10.1002/gepi.20329     Document Type: Article

References (35)

1. Abrams L. 2007. From POF to POI: evolution of a term. Nat Fragile X Foundation Q 29:22.
2. Allen EG, Sullivan AK, Marcus M, Small C, Dominguez C, Epstein MP, Charen K, He W, Taylor KC, Sherman SL. 2007. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 22:2142-2152.
3. Ashley CT, Sutcliffe JS, Kunst CB, Leiner HA, Eichler EE, Nelson DL, Warren ST. 1993. Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG-repeat. Nat Genet 4:244-251.
4. Bell MV, Hirst MC, Nakahori Y, MacKinnon RN, Roche A, Flint TJ, Jacobs PA, Tommerup N, Tranebjaerg L, Froster-Iskenius U, Kerr B, Turner G, Lindenbaum RH, Winter R, Prembrey M, Thibodeau S, Davies KE. 1991. Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell 64:861-866.
5. Brown WT, Houck Jr. GE, Jeziorowska A, Levinson FN, Ding X, Dobkin C, Zhong N, Henderson J, Brooks SS, Jenkins EC. 1993. Rapid fragile X carrier screening and prenatal diagnosis using a nonradioactive PCR test. J Am Med Assoc 270:1569-1575.
6. de Bruin JP, Bovenhuis H, van Noord PA, Pearson PL, van Arendonk JA, te Velde ER, Kuurman WW, Dorland M. 2001. The role of genetic factors in age at natural menopause. Hum Reprod 16:2014-2018.
7. Ennis S, Ward D, Murray A. 2006. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. Eur J Hum Genet 14:253-255.
8. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick Jr. RG, Warren ST, Oostra BA, Nelson DL, Caskey CT. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67:1047-1058.
9. Hagerman PJ, Greco CM, Hagerman RJ. 2003. A cerebellar tremor/ataxia syndrome among fragile X premutation carriers. Cytogenet Genome Res 100:206-212.
10. Hundscheid RD, Braat DD, Kiemeney LA, Smits AP, Thomas CM. 2001. Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives. Hum Reprod 16:457-462.
11. Kenneson A, Zhang F, Hagedorn CH, Warren ST. 2001. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 10:1449-1454.
12. McConkie-Rosell A, Lachiewicz AM, Spiridigliozzi GA, Tarleton J, Schoenwald S, Phelan MC, Goonewardena P, Ding X, Brown WT. 1993. Evidence that methylation of the FMR-I locus is responsible for variable phenotypic expression of the fragile X syndrome. Am J Hum Genet 53:800-809.
13. Meadows KL, Pettay D, Newman J, Hersey J, Ashley AE, Sherman SL. 1996. Survey of the fragile X syndrome and the fragile X E syndrome in a special education needs population. Am J Med Genet 64:428-433.
14. Murabito JM, Yang Q, Fox C, Wilson PW, Cupples LA. 2005. Heritability of age at natural menopause in the Framingham Heart Study. J Clin Endocrinol Metab 90:3427-3430.
15. Murray A, Webb J, MacSwiney F, Shipley EL, Morton NE, Conway GS. 1999. Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women. Hum Reprod 14:1217-1218.
16. Nolin SL, Brown WT, Glicksman A, Houck Jr. GE, Gargano AD, Sullivan A, Biancalana V, Brondum-Nielsen K, Hjalgrim H, Holinski-Feder E, Kooy F, Longshore J, Macpherson J, Mandel JL, Matthijs G, Rousseau F, Steinbach P, Vaisanen ML, von Koskull, Sherman SL. 2003. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 72:454-464.
17. Pankratz VS, de Andrade M, Therneau TM. 2005. Random-effects Cox proportional hazards model: general variance components methods for time-to-event data. Genet Epidemiol 28:97-109.
18. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL. 1991. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66:817-822.
19. Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. 2002. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 8:1482-1488.
20. Self SG, Liang K-Y. 1987. Asymptotic properties of maximum likelihood estimators and likelihood ratio tests under nonstandard conditions. J Am Statist Assoc 82:605-610.
21. Sherman SL. 2000. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 97:189-194.
22. Sherman S, Pletcher BA, Driscoll DA. 2005. Fragile X syndrome: diagnostic and carrier testing. Genet Med 7:584-587.
23. Snieder H, MacGregor AJ, Spector TD. 1998. Genes control the cessation of a wornan's reproductive life: a twin study of hysterectomy and age at menopause. J Clin Endocrinol Metab 83:1875-1880.
24. Sullivan AK, Marcus M, Epstein MP, Allen EG, Anido AE, Paquin JJ, Yadav-Shah M, Sherman SL. 2005. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 20:402-412.
25. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, Warren ST. 1992. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1:397-400.
26. Tassone F, Hagerman PJ. 2003. Expression of the FMR1 gene. Cytogenet Genome Res 100:124-128.
27. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. 2000a. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 66:6-15.
28. Tassone F, Hagerman RJ, Taylor AK, Mills JB, Harris SW, Gane LW, Hagerman PJ. 2000b. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 91:144-152.
29. Therneau TM, Atkinson B. 2007. Kinship: mixed-effects Cox models, sparse matrices, and modeling data from large pedigrees. R package version 1.1.045 (available athttp://www.r-project.org/).
30. Treloar SA, Do KA, Martin NG. 1998. Genetic influences on the age at menopause. Lancet 352:1084-1085.
31. van Asselt KM, Kok HS, Pearson PL, Dubas JS, Peeters PH, Te Velde ER, van Noord PA. 2004. Heritability of menopausal age in mothers and daughters. Fertil Steril 82:1348-1351.
32. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, Eussen BE, van Ommen GJ, Blonden LA, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-914.
33. Vink J, Boomsma D. 2005. Modeling age at menopause. Fertil Steril 83:1068.
34. Welt CK. 2007. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol [epub 29 October 2007].
35. Welt CK, Smith PC, Taylor AE. 2004. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab 89:4569-4574.